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St James’s Hospital, Dublin, Ireland.
Background
Dyslipidaemia, secondary to both HIV and the use of antiretroviral therapy (ART) is well recognised, with HIV replication and
immune status also thought to contribute to the risk. Traditionally the HIV physician has looked after HIV with primary care
physicians (GP) managing non-HIV-related medical issues. However with the ageing population and the effectiveness of ART the
HIV physician is diversifying to focus management strategies on preventative measures also.
Method
127 subjects were recruited. All subjects were HIV-positive males without any traditional cardiovascular disease symptoms or
history. Details of patients demographics, family history, statin therapy, and primary care physician contact were collected.
Baseline parameters were recorded and fasting bloods taken.
Results
127 asymptomatic HIV-positive males were recruited. 74/127 (58.3%) met the EACS criteria for statin prescription. 33/74 (44.6%)
were on a statin. There was no significant difference between the class of antiretroviral prescribed, (NNRTI v PI) and lipid
abnormalities (p0.628). Hypertension and increased waist:hip ratio significantly increased the chances of the patient being
hyperlipidaemic. Patients were more likely to be prescribed a statin if they were older, had hypertension, an increased waist
circumference, increased Framingham risk, increased brain natriuretic peptide (BNP), or were diagnosed HIV-positive for longer
(pB0.05). Pravastatin (21/33 [63.6%]), was most commonly prescribed statin. 24.2% received their statin prescription from their
HIV physician, with 75.8% receiving their prescription from their GP. 5/21 (23.8%) on pravastatin met the target verses 7/7
(100%) on atorvastatin verses 2/2 (100%) on simvastatin versus 1/3 (33.3%) on rosuvastatin (p0.02). Meeting lipid targets was
less successful in the protease inhibitor group (1/9) 11.1% versus 11/21 (52.4%) in the NNRTI group (p0.16).
Conclusion
The majority met criteria for lipid management but less than half of those were prescribed it. Of those, most received treatment
from their GP. Nearly half of those on statins did not meet lipid targets. HIV physicians were most likely to prescribe pravastatin
and those on pravastatin were the least likely to achieve lipid targets when compared to the other statins. HIV physicians need
to diversify their knowledge base and have clearly defined management strategies for the management of dyslipidaemia.
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